Trials / Completed
CompletedNCT06519981
Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-9231 in Healthy Caucasian Participants
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Atridia Pty Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, randomized, double-blind, placebo-controlled study. The objective of this study is to evaluate the safety, tolerability, and PK profile of HRS-9231 injection following a single dose in healthy Caucasian participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-9231or matching placebo | HRS-9231 injection or matching placebo will be administered through IV injection. |
Timeline
- Start date
- 2024-08-21
- Primary completion
- 2024-09-29
- Completion
- 2024-11-27
- First posted
- 2024-07-25
- Last updated
- 2024-12-06
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06519981. Inclusion in this directory is not an endorsement.